4j6s Citations

The N-terminal sequence of tyrosine hydroxylase is a conformationally versatile motif that binds 14-3-3 proteins and membranes.

J Mol Biol 426 150-68 (2014)
Cited: 18 times
EuropePMC logo PMID: 24055376

Abstract

Tyrosine hydroxylase (TH) catalyzes the rate-limiting step in the synthesis of catecholamine neurotransmitters, and a reduction in TH activity is associated with several neurological diseases. Human TH is regulated, among other mechanisms, by Ser19-phosphorylation-dependent interaction with 14-3-3 proteins. The N-terminal sequence (residues 1-43), which corresponds to an extension to the TH regulatory domain, also interacts with negatively charged membranes. By using X-ray crystallography together with molecular dynamics simulations and structural bioinformatics analysis, we have probed the conformations of the Ser19-phosphorylated N-terminal peptide [THp-(1-43)] bound to 14-3-3γ, free in solution and bound to a phospholipid bilayer, and of the unphosphorylated peptide TH-(1-43) both free and bilayer bound. As seen in the crystal structure of THp-(1-43) complexed with 14-3-3γ, the region surrounding pSer19 adopts an extended conformation in the bound state, whereas THp-(1-43) adopts a bent conformation when free in solution, with higher content of secondary structure and higher number of internal hydrogen bonds. TH-(1-43) in solution presents the highest mobility and least defined structure of all forms studied, and it shows an energetically more favorable interaction with membranes relative to THp-(1-43). Cationic residues, notably Arg15 and Arg16, which are the recognition sites of the kinases phosphorylating at Ser19, are also contributing to the interaction with the membrane. Our results reveal the structural flexibility of this region of TH, in accordance with the functional versatility and conformational adaptation to different partners. Furthermore, this structural information has potential relevance for the development of therapeutics for neurodegenerative disorders, through modulation of TH-partner interactions.

Articles - 4j6s mentioned but not cited (6)

  1. Structural basis of O-GlcNAc recognition by mammalian 14-3-3 proteins. Toleman CA, Schumacher MA, Yu SH, Zeng W, Cox NJ, Smith TJ, Soderblom EJ, Wands AM, Kohler JJ, Boyce M. Proc Natl Acad Sci U S A 115 5956-5961 (2018)
  2. The N-terminal sequence of tyrosine hydroxylase is a conformationally versatile motif that binds 14-3-3 proteins and membranes. Skjevik AA, Mileni M, Baumann A, Halskau O, Teigen K, Stevens RC, Martinez A. J Mol Biol 426 150-168 (2014)
  3. Phosphorylation dependence and stoichiometry of the complex formed by tyrosine hydroxylase and 14-3-3γ. Kleppe R, Rosati S, Jorge-Finnigan A, Alvira S, Ghorbani S, Haavik J, Valpuesta JM, Heck AJ, Martinez A. Mol Cell Proteomics 13 2017-2030 (2014)
  4. Structural Analysis of the 14-3-3ζ/Chibby Interaction Involved in Wnt/β-Catenin Signaling. Killoran RC, Fan J, Yang D, Shilton BH, Choy WY. PLoS One 10 e0123934 (2015)
  5. Analysis of SARS-CoV-2 nucleocapsid phosphoprotein N variations in the binding site to human 14-3-3 proteins. Del Veliz S, Rivera L, Bustos DM, Uhart M. Biochem Biophys Res Commun 569 154-160 (2021)
  6. YWHAG Mutations Cause Childhood Myoclonic Epilepsy and Febrile Seizures: Molecular Sub-regional Effect and Mechanism. Ye XG, Liu ZG, Wang J, Dai JM, Qiao PX, Gao PM, Liao WP. Front Genet 12 632466 (2021)


Reviews citing this publication (3)

  1. Complex molecular regulation of tyrosine hydroxylase. Tekin I, Roskoski R, Carkaci-Salli N, Vrana KE. J Neural Transm (Vienna) 121 1451-1481 (2014)
  2. Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Waløen K, Kleppe R, Martinez A, Haavik J. Expert Opin Ther Targets 21 167-180 (2017)
  3. Proteasome-mediated degradation of tyrosine hydroxylase triggered by its phosphorylation: a new question as to the intracellular location at which the degradation occurs. Nakashima A, Kodani Y, Kaneko YS, Nagasaki H, Ota A. J Neural Transm (Vienna) 125 9-15 (2018)

Articles citing this publication (9)

  1. De Novo Mutations in YWHAG Cause Early-Onset Epilepsy. Guella I, McKenzie MB, Evans DM, Buerki SE, Toyota EB, Van Allen MI, Epilepsy Genomics Study, Suri M, Elmslie F, Deciphering Developmental Disorders Study, Simon MEH, van Gassen KLI, Héron D, Keren B, Nava C, Connolly MB, Demos M, Farrer MJ. Am J Hum Genet 101 300-310 (2017)
  2. Calcium-Promoted Interaction between the C2-Domain Protein EHB1 and Metal Transporter IRT1 Inhibits Arabidopsis Iron Acquisition. Khan I, Gratz R, Denezhkin P, Schott-Verdugo SN, Angrand K, Genders L, Basgaran RM, Fink-Straube C, Brumbarova T, Gohlke H, Bauer P, Ivanov R. Plant Physiol 180 1564-1581 (2019)
  3. Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson's disease. Dong Y, Han LL, Xu ZX. Mol Med 24 61 (2018)
  4. Stable preparations of tyrosine hydroxylase provide the solution structure of the full-length enzyme. Bezem MT, Baumann A, Skjærven L, Meyer R, Kursula P, Martinez A, Flydal MI. Sci Rep 6 30390 (2016)
  5. Dissection of binding between a phosphorylated tyrosine hydroxylase peptide and 14-3-3zeta: A complex story elucidated by NMR. Hritz J, Byeon IJ, Krzysiak T, Martinez A, Sklenar V, Gronenborn AM. Biophys J 107 2185-2194 (2014)
  6. Tyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity. Baumann A, Jorge-Finnigan A, Jung-Kc K, Sauter A, Horvath I, Morozova-Roche LA, Martinez A. Sci Rep 6 39488 (2016)
  7. Relevance of Electrostatics for the Interaction of Tyrosine Hydroxylase with Porous Silicon Nanoparticles. Bezem MT, Johannessen FG, Kråkenes TA, Sailor MJ, Martinez A. Mol Pharm 18 976-985 (2021)
  8. Cryo-EM Structure and Activator Screening of Human Tryptophan Hydroxylase 2. Zhu K, Liu C, Gao Y, Lu J, Wang D, Zhang H. Front Pharmacol 13 907437 (2022)
  9. Investigating the Disordered and Membrane-Active Peptide A-Cage-C Using Conformational Ensembles. Dobrovolska O, Strømland Ø, Handegård ØS, Jakubec M, Govasli ML, Skjevik ÅA, Frøystein NÅ, Teigen K, Halskau Ø. Molecules 26 3607 (2021)